Table of Contents
INSIDE BLOOD COMMENTARIES
In this issue of Blood, Marlein et al1 identify a tumor-specific NOX2-dependent transfer of mitochondria from bone marrow stromal cells (BMSCs) to acute myeloid leukemia (AML) cells via AML-derived tunneling nanotubes (see figure), supporting inhibition of NOX2 as a novel therapeutic strategy in AML.
CLINICAL TRIALS AND OBSERVATIONS
Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia
Clinical Trials & Observations
IMMUNOBIOLOGY AND IMMUNOTHERAPY
HDAC6 inhibition upregulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies
THROMBOSIS AND HEMOSTASIS
Publisher's Note: There is an Inside Blood Commentary on this article in this issue.
LETTERS TO BLOOD
A multi-institutional outcomes analysis of patients with relapsed or refractory DLBCL treated with ibrutinib
Mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemia (AML) blasts is driven by NOX2-derived superoxide. The cover image shows a tunneling nanotube formed by the AML blast (orange) and mitochondria (green) from bone marrow stromal cells in the tunneling nanotube. See the article by Marlein et al on page 1649.
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board